Genetic Testing for Breast Cancer Susceptibility
Major Conference:
Genetic Testing for Breast Cancer Susceptibility:
The Science, The Ethics, The Future
November 23, 1996 San Francisco, California
Program
8:30-8:35
Welcome
- Thomas A. Raffin, M.D.
Professor and Chief, Division of Pulmonary and Critical Care Medicine; Co-Director, Stanford Center for Biomedical Ethics; Co-Director, Stanford Program in Genomics, Ethics, and Society
Dean, Stanford University School of Medicine
8:35-8:40
Introductory Remarks
- Jan Leschly
Chief Executive, SmithKline Beecham Corporation
8:40-9:10
Recommendations of the Stanford Program in Genomics, Ethics,
and Society
Professor of Law, Stanford University; Chair, PGES Working Group
9:10-9:40
The Genetics of Breast Cancer
American Cancer Society Professor of Genetics and Medicine, University of Washington, Seattle
9:40-10:10
The Role of the Biotechnology Industry
- Mark Skolnick, Ph.D.
Executive Vice President of Research, Myriad Genetic Laboratories, Inc.
10:10-10:30
Break
10:30-11:00
Ethical Dilemmas in Genetic Testing and Counseling
Director, Center for Bioethics; Trustee Professor, University of Pennsylvania
11:00-11:30
Legal Issues in the Regulation and Use of Genetic Testing
Professor of Law, Chicago-Kent College of Law; Research Fellow, American Bar Foundation; Senior Scholar, Center for Clinical Medical Ethics, University of Chicago
11:30-12:00
Social and Cultural Realities of Predicting Breast Cancer
Risk
Professor of Anthropology, Department of Social Studies of Medicine and Department of Anthropology, McGill University
12:00-1:30
Banquet Lunch and Keynote Address
Director, National Center for Human Genome Research
1:30-2:45
Panel #1: Comparing National Perspectives
Genetic testing for breast cancer from the perspective of a number of countries and cultures.
- Moderator: David R. Cox, M.D., Ph.D.
Professor of Genetics and Pediatrics, Stanford University; Member, PGES Working Group
- Panelists:
Head, Centre for Professional Ethics; Professor of Moral Philosophy, University of Central Lancashire
Neil A. Holtzman, M.D., M.P.H.
Director, Genetic & Public Policy Studies, The Johns Hopkins Medical Institutions; Chair, NIH-DOE ELSI Working Group Task Force on Genetic Testing
Bartha Maria Knoppers, LL.D.
Universite de Montreal, C.R.D.P.
Institute of Biological Sciences; University of Tsukuba, Japan
2:45-3:00
Break
3:00-4:15
Panel #2: The Voices of People at Risk
First-hand accounts and research reports on the impact of genetic testing for breast cancer.
- Moderator: Stefanie Jeffrey, M.D.
Assistant Professor of Surgery, Stanford University; Member, PGES Working Group
- Panelists:
Barbara A. Brenner, J.D.
Executive Director, Breast Cancer Action , San Francisco
June Peters, M.S.
Genetic Counselor, Medical Genetics Branch of the National Center for Human Genome Research of the National Institutes of Health
Nancy Press, Ph.D.
Associate Research Anthropologist, Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine
Professor of Psychiatry & Behavioral Sciences, Stanford University School of Medicine
4:15-4:30
Break
4:30-5:45
Panel #3: Where Do We Go From Here?
The future of genetic testing for breast cancer.
- Moderator: Paul Berg, Ph.D.
Robert W. and Vivian K. Cahill Professor in Cancer Research and Biochemistry; Director, Beckman Center for Molecular and Genetic Medicine, Stanford University; Member, PGES Working Group
- Panelists:
Francis S. Collins, M.D., Ph.D.
Director, National Center for Human Genome Research
Troy Duster, Ph.D.
Director, Institute for the Study of Social Change, University of California, Berkeley
Eric T. Juengst, Ph.D.
Associate Professor of Biomedical Ethics, Center for Biomedical Ethics , Case Western Reserve University
Mary Jo Ellis Kahn, M.S.N., R.N.
Virginia Breast Cancer Foundation; National Breast Cancer Coalition
Karen M. Rothenberg, J.D., M.P.A.
Marjorie Cook Professor of Law and Director, Law and Health Care Program, University of Maryland School of Law
5:45-6:00
Closing Comments
Executive Director and Senior Research Scholar, Stanford Center for Biomedical Ethics; Co-Director, Stanford Program in Genomics, Ethics, and Society
6:00
Reception


